NEW YORK (GenomeWeb News) – Atreca today announced it has licensed immune repertoire capture technology from Stanford University, which the biopharmaceutical company will develop for a broad range of applications.

The technology was developed in the laboratories of William Robinson, an associate professor of medicine in the Division of Immunology and Rheumatology at Stanford, and leverages next-generation sequencing to identify new antibodies that have utility themselves and that define targets of functional immune response.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The US Food and Drug Administration has approved Kite Pharmaceuticals' CAR T-cell therapy for large B-cell lymphomas, the New York Times reports.

Kaiser Health News reports that gene therapies could cost more than a million dollars.

Worcester Polytechnic Institute researchers have received a grant to combine biology and computer science for high school students.

In Nature this week: variants associated with obsessive-compulsive disorder, review of key CRISPR enzymes, and more.